IL272948B2 - enpp1 inhibitors and their use for cancer treatment - Google Patents
enpp1 inhibitors and their use for cancer treatmentInfo
- Publication number
- IL272948B2 IL272948B2 IL272948A IL27294820A IL272948B2 IL 272948 B2 IL272948 B2 IL 272948B2 IL 272948 A IL272948 A IL 272948A IL 27294820 A IL27294820 A IL 27294820A IL 272948 B2 IL272948 B2 IL 272948B2
- Authority
- IL
- Israel
- Prior art keywords
- substituted
- enpp1 inhibitor
- alkyl
- nnmeo
- nmeo
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims 19
- 101150017770 ENPP1 gene Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 101000812677 Homo sapiens Nucleotide pyrophosphatase Proteins 0.000 claims 17
- 102100039306 Nucleotide pyrophosphatase Human genes 0.000 claims 17
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 150000001412 amines Chemical class 0.000 claims 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- -1 phosphonate ester Chemical class 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 3
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 7
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- GKLHVBQIDCCGOC-UHFFFAOYSA-N [4-(6,7-dimethoxyquinazolin-4-yl)cyclohexyl]methyl dihydrogen phosphate Chemical compound P(=O)(OCC1CCC(CC1)C1=NC=NC2=CC(=C(C=C12)OC)OC)(O)O GKLHVBQIDCCGOC-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- RQKYHDHLEMEVDR-UHFFFAOYSA-N oxo-bis(phenylmethoxy)phosphanium Chemical compound C=1C=CC=CC=1CO[P+](=O)OCC1=CC=CC=C1 RQKYHDHLEMEVDR-UHFFFAOYSA-N 0.000 description 2
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- RVZMPNMUBCAPQO-UHFFFAOYSA-N 2,4-dimethoxyquinazoline Chemical compound C1=CC=CC2=NC(OC)=NC(OC)=C21 RVZMPNMUBCAPQO-UHFFFAOYSA-N 0.000 description 1
- PXVVZSGCKNXCGX-UHFFFAOYSA-N 2-[4-(6,7-dimethoxyquinazolin-4-yl)cyclohexyl]ethyl dihydrogen phosphate Chemical compound P(=O)(OCCC1CCC(CC1)C1=NC=NC2=CC(=C(C=C12)OC)OC)(O)O PXVVZSGCKNXCGX-UHFFFAOYSA-N 0.000 description 1
- AWYGMPZJYHBMIB-UHFFFAOYSA-N O(C)C1=C(OC)C=C2C(C3CCC(CO)CC3)=NC=NC2=C1 Chemical compound O(C)C1=C(OC)C=C2C(C3CCC(CO)CC3)=NC=NC2=C1 AWYGMPZJYHBMIB-UHFFFAOYSA-N 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- YGBMCLDVRUGXOV-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 YGBMCLDVRUGXOV-UHFFFAOYSA-N 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
- C07F9/165—Esters of thiophosphoric acids
- C07F9/1651—Esters of thiophosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3826—Acyclic unsaturated acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/44—Amides thereof
- C07F9/4403—Amides thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4407—Amides of acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762556117P | 2017-09-08 | 2017-09-08 | |
| PCT/US2018/050018 WO2019051269A1 (en) | 2017-09-08 | 2018-09-07 | ENPP1 INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL272948A IL272948A (en) | 2020-04-30 |
| IL272948B1 IL272948B1 (en) | 2023-05-01 |
| IL272948B2 true IL272948B2 (en) | 2023-09-01 |
Family
ID=63714052
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL302338A IL302338B2 (en) | 2017-09-08 | 2018-09-07 | Enpp1 inhibitors and their use for the treatment of cancer |
| IL272948A IL272948B2 (en) | 2017-09-08 | 2018-09-07 | enpp1 inhibitors and their use for cancer treatment |
| IL311010A IL311010A (en) | 2017-09-08 | 2018-09-07 | ENPP1 inhibitors and their use for cancer treatment |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL302338A IL302338B2 (en) | 2017-09-08 | 2018-09-07 | Enpp1 inhibitors and their use for the treatment of cancer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL311010A IL311010A (en) | 2017-09-08 | 2018-09-07 | ENPP1 inhibitors and their use for cancer treatment |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11701371B2 (enExample) |
| EP (2) | EP3678668B1 (enExample) |
| JP (2) | JP7292740B2 (enExample) |
| KR (2) | KR20240151869A (enExample) |
| CN (2) | CN111372587B (enExample) |
| AU (2) | AU2018330188C1 (enExample) |
| BR (1) | BR112020004559A2 (enExample) |
| CA (1) | CA3074268A1 (enExample) |
| DK (1) | DK3678668T3 (enExample) |
| EA (1) | EA202090595A1 (enExample) |
| ES (1) | ES2975183T3 (enExample) |
| HU (1) | HUE066413T2 (enExample) |
| IL (3) | IL302338B2 (enExample) |
| MA (1) | MA50082A (enExample) |
| MX (2) | MX2020002646A (enExample) |
| PL (1) | PL3678668T3 (enExample) |
| SG (1) | SG11202001728YA (enExample) |
| WO (1) | WO2019051269A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020140001A1 (en) * | 2018-12-28 | 2020-07-02 | Riboscience Llc | Quinazoline derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors |
| LT3952995T (lt) | 2019-04-12 | 2023-11-10 | Riboscience Llc | Bicikliniai heteroarilo dariniai kaip ektonukleotidų pirofosfatazės fosfodiesterazės 1 inhibitoriai |
| AU2020350190A1 (en) | 2019-09-16 | 2022-05-12 | Aten Porus Lifesciences Pvt. Ltd. | 2-amino-s6-substituted thiopurine compounds as inhibitors of the ENPP1 protein |
| CN116574099A (zh) * | 2019-09-23 | 2023-08-11 | 南京征祥医药有限公司 | 磷酸二酯酶抑制剂及用途 |
| AR121269A1 (es) * | 2020-02-04 | 2022-05-04 | Stingray Therapeutics Inc | Inhibidores de la ectonucleótido pirofosfatasa / fosfodiesterasa 1 (enpp1) y métodos de uso de los mismos |
| TWI874791B (zh) | 2020-02-18 | 2025-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI883391B (zh) | 2020-02-18 | 2025-05-11 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| AR121356A1 (es) | 2020-02-18 | 2022-05-11 | Gilead Sciences Inc | Compuestos antivirales |
| CN115362150A (zh) * | 2020-04-09 | 2022-11-18 | 贝达药业股份有限公司 | Enpp1抑制剂及其组合物和用途 |
| JP7781774B2 (ja) * | 2020-05-04 | 2025-12-08 | ヴォラストラ セラピューティクス，インコーポレーテッド | Ｅｎｐｐ１のイミノスルファノン阻害剤 |
| KR102682428B1 (ko) | 2020-05-08 | 2024-07-05 | 주식회사 티씨노바이오사이언스 | 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 프탈라진 유도체 및 이들의 용도 |
| CN115515939B (zh) | 2020-05-08 | 2024-12-13 | 谛希诺生物科技有限公司 | 具有抑制外核苷酸焦磷酸酶-磷酸二酯酶的活性的新型酞嗪衍生物及它们的用途 |
| WO2021257614A1 (en) * | 2020-06-16 | 2021-12-23 | Volastra Therapeutics, Inc. | Heterocyclic inhibitors of enpp1 |
| WO2022051634A1 (en) * | 2020-09-03 | 2022-03-10 | Immunesensor Therapeutics, Inc. | Quinoline cgas antagonist compounds |
| JP2023549738A (ja) | 2020-10-30 | 2023-11-29 | １シーバイオ， インコーポレイテッド | エクトヌクレオチドピロホスファターゼ－ホスホジエステラーゼ－１（ｅｎｐｐ１）阻害物質及びそれらの使用 |
| EP4259148A4 (en) * | 2020-12-09 | 2025-08-06 | Stingray Therapeutics Inc | PHOSPHONATES AS INHIBITORS OF ENPP1 AND CDNP |
| CN116600813A (zh) * | 2020-12-09 | 2023-08-15 | 斯汀格瑞治疗股份有限公司 | 作为enpp1和cdnp抑制剂的膦酸盐 |
| JP2024504285A (ja) * | 2020-12-29 | 2024-01-31 | ティーエックスイノ バイオサイエンス インコーポレイテッド | エクトヌクレオチドピロホスファターゼ－ホスホジエステラーゼの阻害活性を有する新規のナフチリジノン誘導体及びこれらの用途 |
| KR102720206B1 (ko) | 2020-12-29 | 2024-10-21 | 주식회사 티씨노바이오사이언스 | 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 나프티리딘온 유도체 및 이들의 용도 |
| KR102686866B1 (ko) | 2021-01-29 | 2024-07-19 | 주식회사 티씨노바이오사이언스 | 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 벤조트리아졸 유도체 및 이들의 용도 |
| WO2022164249A1 (ko) | 2021-01-29 | 2022-08-04 | 주식회사 티씨노바이오사이언스 | 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 벤조트리아졸 유도체 및 이들의 용도 |
| WO2022197734A1 (en) * | 2021-03-16 | 2022-09-22 | Riboscience Llc | Bicyclic heteroaryl boronate derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors |
| EP4323362B1 (en) | 2021-04-16 | 2025-05-07 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
| CN115536696B (zh) * | 2021-06-29 | 2023-07-14 | 上海齐鲁制药研究中心有限公司 | Enpp1抑制剂 |
| CA3228162A1 (en) | 2021-08-18 | 2023-02-23 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| EP4395786A4 (en) * | 2021-09-03 | 2025-07-23 | Angarus Therapeutics Inc | ENPP1 INHIBITORS AND IMMUNE CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS |
| WO2023077083A1 (en) * | 2021-10-29 | 2023-05-04 | Angarus Therapeutics, Inc. | Enpp1 inhibitors as inhibitors of metastasis |
| IL315346A (en) | 2022-03-02 | 2024-11-01 | Immunesensor Therapeutics Inc | CGAS agonistic quinoline compounds |
| US20250206763A1 (en) * | 2022-04-11 | 2025-06-26 | Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. | Enpp1 inhibitor |
| EP4514331A1 (en) | 2022-04-29 | 2025-03-05 | Petragen, Inc. | Inhibitors of enpp1 and modulation of bone growth |
| CN114767863B (zh) * | 2022-04-29 | 2024-01-30 | 西北工业大学 | 一种enpp2基因或蛋白在调控结直肠癌细胞中的应用 |
| JP2025527243A (ja) * | 2022-08-01 | 2025-08-20 | スラバティ エーアイ テクノロジー プライベート リミテッド | 新規なエクトヌクレオチドピロホスファターゼ／ホスホジエステラーゼ１（ｅｎｐｐ－１）阻害剤およびその使用 |
| WO2024213932A1 (en) * | 2023-04-11 | 2024-10-17 | The Hong Kong University Of Science And Technology | Driving axon regeneration by novel enpp1 inhibitors |
| WO2024216211A2 (en) * | 2023-04-14 | 2024-10-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of inhibiting tumor progression and metastasis by inhibition of enpp1 |
| WO2025207514A1 (en) * | 2024-03-25 | 2025-10-02 | Riboscience Llc | Bicyclic heteroaryl sulfanediimine derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8883791B2 (en) * | 2010-09-29 | 2014-11-11 | Intervet Inc. | N-heteroaryl compounds with cyclic bridging unit for the treatment of parasitic diseases |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA228044A (en) | 1923-01-16 | Thomas Noble Boughton | Die for forming bolts | |
| CA190896A (en) | 1919-02-24 | 1919-06-17 | Josephat C. Bergeron | Advertising device |
| DE3319795A1 (de) | 1983-06-01 | 1984-12-06 | Hoechst Ag, 6230 Frankfurt | Verfahren zur herstellung von phosphonsaeureestern |
| US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
| PT831100E (pt) | 1995-04-21 | 2001-01-31 | Teikoku Hormone Mfg Co Ltd | Novos derivados de peptido |
| US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
| AU2002254152A1 (en) * | 2001-03-08 | 2002-09-24 | Millennium Pharmaceuticals | (homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases |
| US20040101840A1 (en) * | 2001-04-27 | 2004-05-27 | Chung Leland W.K. | Identification, cloning and characterization of a novel pc-1 gene differentially expressed in prostate cells and tissues |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| ATE438644T1 (de) | 2002-12-24 | 2009-08-15 | Astrazeneca Ab | Chinazolinderivate |
| US20070004763A1 (en) | 2005-06-10 | 2007-01-04 | Nand Baindur | Aminoquinoline and aminoquinazoline kinase modulators |
| US10543207B2 (en) | 2008-12-31 | 2020-01-28 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| US8980865B2 (en) | 2011-12-22 | 2015-03-17 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| JP2016518140A (ja) | 2013-05-03 | 2016-06-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｉ型インターフェロンの環状ジヌクレオチド誘導法 |
| SI2996473T1 (sl) | 2013-05-18 | 2019-12-31 | Aduro Biotech, Inc. | Sestavki in postopki za aktiviranje signaliziranja, odvisnega od "stimulator interferonskih genov" |
| JP6615207B2 (ja) * | 2014-09-22 | 2019-12-04 | ユ−シェン チャオ | 複素環式化合物及びその使用 |
| WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
| CN105153153A (zh) | 2015-08-31 | 2015-12-16 | 吉林奥来德光电材料股份有限公司 | 一种新的芳香族胺类化合物及其制备与应用 |
| TWI659949B (zh) | 2016-05-16 | 2019-05-21 | 臺北醫學大學 | 組蛋白去乙醯酶6抑制劑及其用途 |
| WO2018119325A1 (en) | 2016-12-22 | 2018-06-28 | Mavupharma, Inc. | Compositions and methods of enhancing or augmenting type i ifn production |
| US20190327974A1 (en) | 2017-01-09 | 2019-10-31 | The Australian National University | Synergists for improved pesticides |
| US10518257B2 (en) | 2017-05-04 | 2019-12-31 | Exxonmobil Research And Engineering Company | Metal organic frameworks, their synthesis and use |
| WO2018229139A1 (en) | 2017-06-14 | 2018-12-20 | Fundación Para La Investigación Médica Aplicada | Novel compounds for use in cancer |
| CR20200140A (es) | 2017-08-31 | 2020-05-15 | Abbvie Inc | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos |
| CA3128044A1 (en) | 2019-02-01 | 2020-08-06 | The Board Of Trustees Of The Leland Stanford Junior University | Enpp1 inhibitors and methods of modulating immune response |
| CN114437128B (zh) * | 2022-01-28 | 2023-12-19 | 中国科学院长春应用化学研究所 | 一种胆碱磷酸修饰的紫杉醇药物及其制备方法和应用 |
-
2018
- 2018-09-07 PL PL18779884.8T patent/PL3678668T3/pl unknown
- 2018-09-07 DK DK18779884.8T patent/DK3678668T3/da active
- 2018-09-07 KR KR1020247033122A patent/KR20240151869A/ko active Pending
- 2018-09-07 CN CN201880063793.8A patent/CN111372587B/zh active Active
- 2018-09-07 IL IL302338A patent/IL302338B2/en unknown
- 2018-09-07 MA MA050082A patent/MA50082A/fr unknown
- 2018-09-07 EP EP18779884.8A patent/EP3678668B1/en active Active
- 2018-09-07 WO PCT/US2018/050018 patent/WO2019051269A1/en not_active Ceased
- 2018-09-07 EP EP24150802.7A patent/EP4327882A3/en not_active Withdrawn
- 2018-09-07 KR KR1020207007008A patent/KR102715420B1/ko active Active
- 2018-09-07 JP JP2020513331A patent/JP7292740B2/ja active Active
- 2018-09-07 IL IL272948A patent/IL272948B2/en unknown
- 2018-09-07 ES ES18779884T patent/ES2975183T3/es active Active
- 2018-09-07 EA EA202090595A patent/EA202090595A1/ru unknown
- 2018-09-07 IL IL311010A patent/IL311010A/en unknown
- 2018-09-07 US US16/645,300 patent/US11701371B2/en active Active
- 2018-09-07 CN CN202311760294.3A patent/CN117883449A/zh active Pending
- 2018-09-07 CA CA3074268A patent/CA3074268A1/en active Pending
- 2018-09-07 BR BR112020004559-4A patent/BR112020004559A2/pt not_active Application Discontinuation
- 2018-09-07 MX MX2020002646A patent/MX2020002646A/es unknown
- 2018-09-07 AU AU2018330188A patent/AU2018330188C1/en active Active
- 2018-09-07 SG SG11202001728YA patent/SG11202001728YA/en unknown
- 2018-09-07 HU HUE18779884A patent/HUE066413T2/hu unknown
-
2020
- 2020-03-06 MX MX2023007193A patent/MX2023007193A/es unknown
-
2022
- 2022-09-30 US US17/957,392 patent/US11707471B2/en active Active
-
2023
- 2023-05-16 US US18/197,877 patent/US20230277570A1/en active Pending
- 2023-05-31 JP JP2023089900A patent/JP7607969B2/ja active Active
-
2024
- 2024-01-10 AU AU2024200148A patent/AU2024200148A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8883791B2 (en) * | 2010-09-29 | 2014-11-11 | Intervet Inc. | N-heteroaryl compounds with cyclic bridging unit for the treatment of parasitic diseases |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272948B2 (en) | enpp1 inhibitors and their use for cancer treatment | |
| JP2020533288A5 (enExample) | ||
| ES2897422T3 (es) | Compuestos pirroles como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos | |
| US11248012B2 (en) | Phospholipidation of imidazoquinolines and oxoadenines | |
| JP7787063B2 (ja) | オーロラキナーゼ阻害剤およびその使用 | |
| WO2016005276A1 (en) | Process for preparing fluorinated iminopyridine compounds | |
| KR102305710B1 (ko) | Gpr84 수용체 길항제 및 이의 용도 | |
| RS54679B1 (sr) | Sinteza dinatrijum soli n4-(2,2-dimetil-4-[(dihidrogen fosfonoksi)metil]-3-okso-5-pirido[1,4]oksazin-6-il)-5-fluoro-n2-(3,4,5-trimetoksifenil)-2,4-pirimidindiamina | |
| JP2023505239A (ja) | 新規オーロラキナーゼ阻害剤およびその使用 | |
| Cytlak et al. | Synthesis of trifluoromethyl γ-aminophosphonates by nucleophilic aziridine ring opening | |
| CA2944805C (en) | Phenanthroline phosphonic acid derivative and preparation method therefor and application thereof | |
| JP4152353B2 (ja) | 殺菌性ピリジン化合物 | |
| Li et al. | Efficient synthesis of organic sulfonic acid derivatives containing dithiocarbamate side chains | |
| Cal | A convenient synthesis of 2-hydrazinoethylphosphonic acid and derivatives | |
| PL422341A1 (pl) | Tiosemikarbazony alfa -ketofosfonianów dialkilowych oraz sposób ich wytwarzania | |
| HK40064501A (en) | Pyrrole inhibitors of erk protein kinase, synthesis thereof and intermediates thereto | |
| JP5114902B2 (ja) | ビピリジンジオール誘導体の製造方法 | |
| Kumar et al. | One‐Pot Synthesis and Antimicrobial Activity of Novel α‐Aminophosphonates Using TMG | |
| JP2021075535A (ja) | ピリミジン誘導体およびそれらの中間体を調製する化学的方法 | |
| Reddy et al. | SYNTHESIS OF 2-[AMINO ACID ESTER/BIS-(2-CHLOROETHYL) AMINO]-6-METHYL-4H-1, 3, 2-DIOXAPHOSPHORINO (5, 4-b) PYRIDINE 2-SULFIDES | |
| PL231475B1 (pl) | Kwasy α-aminofosfonowe wywodzące się z acetylopirydyny i sposób ich wytwarzania | |
| HK1247910B (en) | Pyrrole compounds as inhibitors of erk protein kinases and pharmaceutical compositions containing these compounds | |
| PL236274B1 (pl) | Sposób otrzymywania alanin podstawionych cytozyną w pozycji β | |
| HK1181384B (en) | Method for producing substituted pyridin-2-one | |
| PL231856B1 (pl) | Diastereoselektywny sposób wytwarzania kwasów alfa-aminofosfonowych |